Q-omics provides the consensus-scored FCHSD2 profile across patient tissues and cancer cell-line models. FCHSD2 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, FCHSD2 is differentially expressed in 9, with the highest sampling consensus in HNSC. Additionally, FCHSD2 protein abundance shows 22,936 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight HNSC, and LSCC as cancer lineages where FCHSD2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FCHSD2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FCHSD2 survival associations across molecular data types. FCHSD2 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (4) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FCHSD2 RNA expression–survival associations across cancer types. High FCHSD2 expression shows unfavorable associations in ACC and KICH, but favorable associations in HNSC, LUAD, LGG and BRCA. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for FCHSD2 RNA expression.
This table summarizes FCHSD2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9, while mass-spec protein shows differences in 5. The strongest signals are observed in HNSC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for FCHSD2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FCHSD2 shows lower tumor expression in KICH, LUSC and LUAD and higher tumor expression in HNSC, KIRC and CHOL. The HNSC box plot shows higher FCHSD2 RNA expression in tumor versus normal tissue (log2 FC = +1.299, t-test p < 0.001).
This table shows molecular features associated with FCHSD2 in patient tissues and cancer cell lines. In patient samples, FCHSD2 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, FCHSD2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and BLOOD_Lymphoma.
